HYDOA
Hydrix Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-17.94%
Annual Growth
2 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Hydrix Limited - Option Expiring 31-Mar-2024
📈 Performance
Price History
-43.75%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in HYDOA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in HYDOA
N/A
HYDOA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in HYDOA also invest in...
Want more shares? Try these...
HYGG.AX was created on 2014-06-01 by Hyperion. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to achieve long-term returns above the benchmark, and minimise the risk of permanent capital loss
📊 Share price
$3.73 AUD
Hexima Ltd. is a biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-12-01. The firm is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The firm is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. The company is also investigating the application of its plant defensin technology to other human fungal diseases.
📊 Share price
$0.01 AUD
Hydrix Ltd. engages in the development, design, and commercialization of technologies in the micro-electronic-mechanical systems (MEMS) sensor industry. The company is headquartered in Mulgrave, Victoria and currently employs 70 full-time employees. The company went IPO on 2001-05-11. The company is focused on the development of cardiovascular product technologies and venture investment in early stage MedTech clients. The firm's segments include Hydrix Services, Hydrix Medical and Hydrix Ventures. The Hydrix Services segment offers a range of engineering and regulatory services, including software, electronics, mechanical, industrial design, and general product development services. Its product development and commercialization services range from applied research through all stages of engineering design, development, prototyping, manufacturer management. The Hydrix Medical segment distributes cardiac monitoring and diagnostic medical device technologies, including the AngelMed Guardian and Phyzhon’s PHYRARI FFR-WIRE product. The Hydrix Ventures segment is engaged in investments in medical technologies.
📊 Share price